| [1] |
Sands BE, Katz S, Wolf DC, et al. A randomised, double-blind, sham-controlled study of granulocyte/ monocyte apheresis for moderate to severe Crohn's disease [J]. Gut, 2013, 62(9): 1288–1294.
|
| [2] |
McCabe RP Jr, Chow CJ, Rothenberger DA. Duodenal-pleural fistula in Crohn's disease: successful long-term medical management [J]. Inflamm Bowel Dis，2013，19(3)：E38–E39.
|
| [3] |
Tlaxca JL, Rychak JJ, Ernst PB, et al. Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease [J]. J Control Release, 2013, 165 (3) : 216–225.
|
| [4] |
Alters SE, McLaughlin B, Spink B, et al. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model [J]. PLoS One, 2012, 7(11): e50630.
|
| [5] |
Yu SY, Qi R. Role of bad in podocyte apoptosis induced by puromycin aminonucleoside [J]. Transplant Proc, 2013, 45 (2): 569–573.
|
| [6] |
Russo E, Petts G, Lloyd T, et al. PMO-255 The expression of interleukin 2 receptor in intestinal resection specimens from patients with Crohn' s disease as assessed by immunohistochemistry[J]. Gut, 2012, 61(Suppl 2) : A179–A179.
|
| [7] |
杭桂芳，武心萍，丁文波.克罗恩病的超声诊断价值[J].中华现代影像学杂志，2006(6)：538–539.
|
| [8] |
Eaden J A, Ford AC. Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease [J]. Gut, 2013, 62 (4): 653.
|
| [9] |
Qi R, Li W, Yu S. FK506 inhibits the mice glomerular mesangial cells proliferation by affecting the transforming growth factor-β and Smads signal pathways [J]. Ren Fail, 2014, 36(4) : 589–592.
|
| [10] |
Peyrin-Biroulet L, Billioud V, D'Haens G, et al. Development of the Paris definition of early Crohn' s disease for disease-modification trials: results of an international expert opinion process [J]. Am J Gastroenterol, 2012, 107(12) : 1770–1776.
|
| [11] |
Burmester G R, Panaccione R, Gordon K B, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease[J]. Ann Rheumat Dis, 2013, 72(4): 517–524.
|
| [12] |
刘畅，徐辉雄，刘畅.进一步提高经腹超声评估炎症性肠病的水平[J].世界华人消化杂志，2013，21(32)：3467–3472.
|
| [13] |
曾美英，吴春根，程英升.炎症性肠病分子影像学的研究进展[J].世界华人消化杂志，2014，22(23)：3424–3429.
|
| [14] |
宋敏.小肠间质瘤的临床诊治分析[J].中国医药指南，2014，12 (24):11–13.
|
| [15] |
Tye GA, Desser TS. MDCT of the Small Bowel [J]. Appl Radiol, 2012, 41(8) : 6–17.
|
| [16] |
李元新.克罗恩病肠梗阻的外科治疗[J].中华消化外科杂志，2014, 13(8) : 12–15.
|
| [17] |
Sandborn WJ, Colombel JF, D'Haens G, et al. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn' s disease [J]. Curr Med Res Opin, 2013, 29(5): 483–493.
|
| [18] |
Bakker SF, Dik VK, Witte BI, et al. Increase in bone mineral density in strictly treated Crohn' s disease patients with concomitant calcium and vitamin D supplementation [J]. J Crohns Colitis, 2013, 7(5) : 377–384.
|
| [19] |
Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease [J]. Ann Rheum Dis, 2013, 72(4): 517–524.
|
| [20] |
Basseri RJ, Nemeth E, Vassilaki ME, et al. Hepcidin is a key mediator of anemia of inflammation in Crohn' s disease [J]. J Crohns Colitis, 2013, 7(8): e286–e291.
|